Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
IntroductionTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer resistant to endocrine and targeted therapies. Immune checkpoint inhibitors (ICIs) have shown significant efficacy in various cancers. Taraxacum officinale, commonly known as dandelion, has traditionally been...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1536406/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589925678055424 |
|---|---|
| author | Tangyi Wang Yadian Lei Jingwei Sun Li Wang Yuxin Lin Zhijing Wu Shoude Zhang Chengzhu Cao Chengzhu Cao Chengzhu Cao Haiyan Wang Haiyan Wang Haiyan Wang |
| author_facet | Tangyi Wang Yadian Lei Jingwei Sun Li Wang Yuxin Lin Zhijing Wu Shoude Zhang Chengzhu Cao Chengzhu Cao Chengzhu Cao Haiyan Wang Haiyan Wang Haiyan Wang |
| author_sort | Tangyi Wang |
| collection | DOAJ |
| description | IntroductionTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer resistant to endocrine and targeted therapies. Immune checkpoint inhibitors (ICIs) have shown significant efficacy in various cancers. Taraxacum officinale, commonly known as dandelion, has traditionally been used to treat breast-related diseases and is recognized for its beneficial composition and low side effects. FDA-approved drugs, having undergone rigorous validation for their safety, efficacy, and quality, provide a foundation for drug repurposing research. Researchers may explore FDA-approved drugs targeting the potential target NANOS1 for TOE (Taraxacum officinale extract) treatment to develop innovative therapeutic strategies. In this context, Dig (Digoxin) and AA (Algestone acetophenide) have been identified as potential drug candidates for further exploration of their therapeutic effects and application potential in targeting NANOS1.MethodsRNA sequencing (RNA-seq) was employed to identify potential targets for triple-negative breast cancer (TNBC) from TOE. Bioinformatics tools, including bc-GenExMiner v4.8, the Human Protein Atlas, and the TIMER database, were utilized for target identification. Molecular docking studies assessed FDA-approved drugs interacting with these targets, with Dig and AA selected as candidate drugs. The therapeutic efficacy of Dig and AA in combination with PD-1 inhibitors was evaluated using the 4T1 mouse model. Flow cytometry was applied to assess lymphocyte infiltration in the tumor immune microenvironment. RNA-seq analysis after target silencing by small interfering RNA (siRNA) was performed, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Validation of findings was conducted through quantitative PCR and Western blot analysis.ResultsTOE inhibited TNBC cell growth, migration, and invasion, as assessed by CCK-8 and transwell assays. RNA-seq indicated the effects may be due to NANOS1 down-regulation. Survival analysis showed lower NANOS1 expression correlated with better prognosis. Immunoinfiltration analysis indicated a negative correlation between NANOS1 levels and activated NK cells. Molecular docking identified Dig and AA as high-affinity binders of NANOS1. Animal experiments showed Dig and PD-1 inhibitor combination enhanced immunotherapy efficacy for TNBC.DiscussionThe findings from this study suggest that TOE may offer a novel therapeutic approach for TNBC by targeting NANOS1, a protein whose down-regulation is associated with improved patient outcomes. The negative correlation between NANOS1 and activated NK cells highlights the potential role of the immune system in TNBC pathogenesis and response to treatment. The identification of Dig as potential drugs targeting NANOS1 provides a new direction for drug repurposing in TNBC. The synergistic effect of Dig and PD-1 inhibition observed in animal models is promising and warrants further investigation into the role of immunotherapy in TNBC treatment. Overall, this study identifies NANOS1 as a new target for TNBC therapy and suggests a combination therapy approach that could enhance immunotherapy effectiveness and improve patient outcomes. |
| format | Article |
| id | doaj-art-9787300e365a4f969abe14f8f033ca86 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9787300e365a4f969abe14f8f033ca862025-01-24T05:21:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15364061536406Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironmentTangyi Wang0Yadian Lei1Jingwei Sun2Li Wang3Yuxin Lin4Zhijing Wu5Shoude Zhang6Chengzhu Cao7Chengzhu Cao8Chengzhu Cao9Haiyan Wang10Haiyan Wang11Haiyan Wang12Department of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaDepartment of Medical Laboratory, Qinghai Provincial People’s Hospital, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaState Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaResearch Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, ChinaKey Laboratory of the Ministry of High Altitude Medicine, Qinghai University, Xining, Qinghai, ChinaDepartment of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, ChinaResearch Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, ChinaKey Laboratory of the Ministry of High Altitude Medicine, Qinghai University, Xining, Qinghai, ChinaIntroductionTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer resistant to endocrine and targeted therapies. Immune checkpoint inhibitors (ICIs) have shown significant efficacy in various cancers. Taraxacum officinale, commonly known as dandelion, has traditionally been used to treat breast-related diseases and is recognized for its beneficial composition and low side effects. FDA-approved drugs, having undergone rigorous validation for their safety, efficacy, and quality, provide a foundation for drug repurposing research. Researchers may explore FDA-approved drugs targeting the potential target NANOS1 for TOE (Taraxacum officinale extract) treatment to develop innovative therapeutic strategies. In this context, Dig (Digoxin) and AA (Algestone acetophenide) have been identified as potential drug candidates for further exploration of their therapeutic effects and application potential in targeting NANOS1.MethodsRNA sequencing (RNA-seq) was employed to identify potential targets for triple-negative breast cancer (TNBC) from TOE. Bioinformatics tools, including bc-GenExMiner v4.8, the Human Protein Atlas, and the TIMER database, were utilized for target identification. Molecular docking studies assessed FDA-approved drugs interacting with these targets, with Dig and AA selected as candidate drugs. The therapeutic efficacy of Dig and AA in combination with PD-1 inhibitors was evaluated using the 4T1 mouse model. Flow cytometry was applied to assess lymphocyte infiltration in the tumor immune microenvironment. RNA-seq analysis after target silencing by small interfering RNA (siRNA) was performed, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Validation of findings was conducted through quantitative PCR and Western blot analysis.ResultsTOE inhibited TNBC cell growth, migration, and invasion, as assessed by CCK-8 and transwell assays. RNA-seq indicated the effects may be due to NANOS1 down-regulation. Survival analysis showed lower NANOS1 expression correlated with better prognosis. Immunoinfiltration analysis indicated a negative correlation between NANOS1 levels and activated NK cells. Molecular docking identified Dig and AA as high-affinity binders of NANOS1. Animal experiments showed Dig and PD-1 inhibitor combination enhanced immunotherapy efficacy for TNBC.DiscussionThe findings from this study suggest that TOE may offer a novel therapeutic approach for TNBC by targeting NANOS1, a protein whose down-regulation is associated with improved patient outcomes. The negative correlation between NANOS1 and activated NK cells highlights the potential role of the immune system in TNBC pathogenesis and response to treatment. The identification of Dig as potential drugs targeting NANOS1 provides a new direction for drug repurposing in TNBC. The synergistic effect of Dig and PD-1 inhibition observed in animal models is promising and warrants further investigation into the role of immunotherapy in TNBC treatment. Overall, this study identifies NANOS1 as a new target for TNBC therapy and suggests a combination therapy approach that could enhance immunotherapy effectiveness and improve patient outcomes.https://www.frontiersin.org/articles/10.3389/fonc.2024.1536406/fullimmune checkpoint blockadetriple-negative breast cancermalignant phenotypenanos1PD-1 inhibitorstumor microenvironments |
| spellingShingle | Tangyi Wang Yadian Lei Jingwei Sun Li Wang Yuxin Lin Zhijing Wu Shoude Zhang Chengzhu Cao Chengzhu Cao Chengzhu Cao Haiyan Wang Haiyan Wang Haiyan Wang Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment Frontiers in Oncology immune checkpoint blockade triple-negative breast cancer malignant phenotype nanos1 PD-1 inhibitors tumor microenvironments |
| title | Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment |
| title_full | Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment |
| title_fullStr | Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment |
| title_full_unstemmed | Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment |
| title_short | Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment |
| title_sort | targeting nanos1 in triple negative breast cancer synergistic effects of digoxin and pd 1 inhibitors in modulating the tumor immune microenvironment |
| topic | immune checkpoint blockade triple-negative breast cancer malignant phenotype nanos1 PD-1 inhibitors tumor microenvironments |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1536406/full |
| work_keys_str_mv | AT tangyiwang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT yadianlei targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT jingweisun targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT liwang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT yuxinlin targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT zhijingwu targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT shoudezhang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT chengzhucao targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT chengzhucao targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT chengzhucao targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT haiyanwang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT haiyanwang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment AT haiyanwang targetingnanos1intriplenegativebreastcancersynergisticeffectsofdigoxinandpd1inhibitorsinmodulatingthetumorimmunemicroenvironment |